Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glucocorticoid-Induced TNF Receptor-Related Protein (GITR), also known as TNFRSF18 or CD357, is a type I transmembrane protein belonging to the tumor necrosis factor receptor superfamily (TNFRSF). It is constitutively expressed at high levels on regulatory T cells (Tregs) and upregulated upon activation in all T cell subsets. GITR interacts with its ligand, GITRL, which is expressed by antigen-presenting cells. GITR functions as a co-stimulatory molecule, enhancing T cell activation, proliferation, and cytokine production. It also plays a regulatory role in modulating the balance between immune activation and suppression, and is targeted for cancer immunotherapy.
Agonist anti-GITR antibodies enhance anti-tumor immunity by boosting effector functions while reducing immunosuppression from regulatory populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glucocorticoid-Induced TNF Receptor-Related Protein (GITR).